Zanaflex
Product Images NDC 16590-871

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Zanaflex (NDC 16590-871). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Zanaflex 4mg Lab 871)

Zanaflex 4mg capsules label with 84 capsules count, distributed by STAT RX USA LLC, Gainesville, GA. Contains each capsule with 4.58mg Tizanidine HCl equivalent to 4mg Tizanidine base. Includes NDC 16590-871-62, manufacturer details (Acorda Therapeutics, Inc., Hawthorne, NY), storage instructions, and warnings about drowsiness and alcohol use.*

FDA Label Image

Label Image (Zanaflex 6mg Lab 756)

Zanaflex 6 mg capsules packaging label showing a quantity of 60 capsules. The label identifies the product as a generic for tizanidine hydrochloride, equivalent to 6 mg tizanidine base per capsule. It is packaged and distributed by Stat RX USA LLC, with manufacturer information for Acorda Therapeutics, Inc., Hawthorne, NY. The label includes a caution to keep out of reach of children and storage instructions for temperature between 59 and 86 degrees Fahrenheit.*

FDA Label Image

Figure 1 (Zanaflex Fig1)

A line graph depicting plasma tizanidine concentration (ng/mL) over time (hours from dosing) for 4 mg doses of tizanidine tablets and capsules, with and without food. The x-axis shows hours from dosing up to 24, and the y-axis shows plasma concentration up to 6 ng/mL, comparing the effects of food and formulation on drug concentration over time.*

FDA Label Image

Figure 2 (Zanaflex Fig2)

A line graph showing improvement in Ashworth Score over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph plots hours post-dose on the x-axis and improvement in Ashworth Score on the y-axis, illustrating greater improvement with 16 mg compared to 8 mg and placebo.*

FDA Label Image

Figure 3 (Zanaflex Fig3)

A line chart comparing improvement in Ashworth Score over three time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). It plots two groups, 'tizanidine (mean dose 28.8 mg)' and 'placebo', showing greater improvement for tizanidine at each time point with error bars indicating variability.*

FDA Label Image

Structure Image (Zanaflex Structure)

Chemical structure of the active ingredient in ZANAFLEX, showing a chlorinated benzene ring fused with a thiadiazole ring and a linked piperazine moiety, with an associated hydrochloride group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.